Background: In clinical practice, analgesic drug doses applied during general anaesthesia are considered sufficient when clinical responses (e.g. movement, blood pressure and heart rate elevations) are suppressed during noxious stimulation. We investigated whether absent clinical responses are indicative of suppressed spinal and brain responsiveness to noxious stimulation in anaesthetised subjects. Methods: Ten healthy volunteers were investigated during deep propofol anaesthesia supplemented with increasing doses of remifentanil in a stepwise manner. Noxious electrical stimuli at an intensity comparable with surgical stimulation were repeatedly administered at each targeted remifentanil concentration. During stimulation, we monitored both clinical responses (blood pressure, heart rate, and movement) and neuronal responses. Neuronal responses were assessed using functional magnetic resonance imaging, spinal reflex responses, and somatosensory evoked potentials. Results: This monitoring combination was able to faithfully detect brain and spinal neuronal responses to the noxious stimulation. Although clinical responses were no longer detected at analgesic dosages similar to those used for general anaesthesia in clinical practice, spinal and brain neuronal responses were consistently observed. Opioid doses that are significantly larger than is usually used in clinical practice only reduced neuronal responses to 41% of their maximal response. Conclusions: Nociceptive activation persists during deep general anaesthesia despite abolished clinical responses. Absent clinical responses are therefore not indicative of absent nociception-specific activation. Thus, commonly accepted clinical responses might be inadequate surrogate markers to assess anti-nociception during general anaesthesia. Further research is required to investigate whether persistent nociception causes adverse effects on patient outcome.
Editor's key points
During anaesthesia, analgesic drugs are commonly titrated according to clinical responses to noxious stimuli. The authors used functional imaging and spinal neurophysiological monitoring to assess nociception simultaneous with clinical responses during general anaesthesia. Opioid doses that prevented clinical responses, attenuated, but did not obliterate, spinal and cortical responses. Absence of clinical responses to noxious stimuli does not necessarily imply absence of nociception.
More than 230 million major surgical procedures requiring anaesthesia are conducted worldwide each year. 1 General anaesthesia, the most common form of anaesthesia, is performed by joint administration of a hypnotic drug and a strong analgesic. While an adequate dose of a hypnotic drug is required to induce unconsciousness and prevent memory formation, 2 a sufficient level of suppression of nociception (i.e.
antinociception) is required to prevent arousal, body movements, haemodynamic changes, 3, 4 neuroendocrine, and metabolic stress responses. 5, 6 In current clinical practice, the general consensus is that a sufficient level of antinociception has been reached when clinical responses such as body movement and heart rate or blood pressure elevations no longer occur during surgical stimulation. In this study, we sought to investigate whether the absence of such clinical responses during deep general anaesthesia indeed indicates the absence of spinal and brain responses to noxious stimuli or to what extent such responses still occur during standard, clinically sufficient, general anaesthesia.
To cover both spinal and brain nociceptive processing, we combined three neurophysiological methods in one setup. Spinal responses to noxious stimulation were assessed via nociception-specific spinal flexion reflex responses using electromyography. Brain responses to noxious stimulation were assessed by monitoring the activity in those brain regions that were found to be activated when contrasting intense noxious vs innocuous stimuli using functional magnetic resonance imaging (fMRI), supplemented by simultaneous recording of somatosensory evoked potentials using electroencephalography (EEG).
Methods

Participants
We conducted this study with 10 healthy volunteers after approval by the local ethics committee (reference number ZS EK 14 005/10, Ethikkommission des Landes Berlin, Landesamt fü r Gesundheit und Soziales) and the German federal drug agency (reference number 4038410, Bundesinstitut fü r Arzneimittel und Medizinprodukte). The study was registered at the German register for clinical trials (Deutsches Register Klinischer Studien, registration number DRKS00000663).
After providing written informed consent, all participants underwent the hospital's standard anaesthesia preparation procedure, which included providing a detailed medical history and undergoing a clinical examination. Additionally, all participants underwent test measurement sessions of the nociceptive flexion reflex and anatomic MRI scans to accustom the participants to the procedures.
Anaesthetic procedure
Anaesthesia was induced by the infusion of propofol using target-controlled infusion pumps (Injectomat TIVA Agilia; Fresenius Kabi, Bad Homburg, Germany). 7 The propofol effectsite concentration was initially adjusted to 4 mg ml À1 for all subjects. Before and during anaesthesia induction a tightfitting facemask was applied to monitor ventilation and respiratory gases. After the loss of consciousness, defined as a state during which the subjects could not be aroused by strong innocuous stimuli ('shaking and shouting'), a laryngeal mask (LMA Unique; LMA, San Diego, CA, USA) was inserted to facilitate monitoring and assistance of ventilation. Ventilation was assisted using the pressure support ventilation mode of the anaesthesia workstation, which automatically switches to a pressure-controlled ventilation mode during apnoea (Dr€ ager Fabius MRI, Dr€ agerwerk, Lü beck, Germany). Pressure levels in both ventilation modes were continually adapted throughout the course of the study to maintain stable end-tidal CO 2 levels at the individual level before induction of anaesthesia. By this method, the individual end-tidal CO 2 level varied no more than 0e2.2% (0e0.1 kPa) from the individual means (4.6e5.6 kPa) across all remifentanil concentrations (see supplementary appendix for details). For nine subjects, who did not tolerate the insertion of the laryngeal mask at an effect-site concentration of 4 mg ml À1 , the effect-site concentration was increased intermittently to 6 mg ml À1 (eight subjects) or 8 mg ml À1 (one subject) to facilitate insertion. After insertion, the propofol effect-site concentration was decreased back to the lowest individual level that ensured stable unconsciousness without arousal during innocuous ('shaking and shouting') and noxious stimulation (4 and 5 mg ml À1 for eight and two subjects, respectively). These individual effect-site concentrations of propofol were then kept stable throughout all measurements. Additional administration of the opioid remifentanil was performed via targetcontrolled infusion pumps to achieve stable effect-site concentrations of 0, 1, 2, 4, 8 ng ml À1 (in ascending order). 8 At each remifentanil concentration, after increasing the targeted effect-site concentration, we waited until the pharmacokinetic/pharmacodynamic (PK/PD) model indicated that the targeted effect-site concentration was reached [time to reach 99% of the target concentration (range): 52e70 s] plus another 5 min (approximately 2e4 equilibration half-life periods of remifentanil 8, 9 ) to account for individual differences. Sets of measurements to monitor clinical and spinal and brain responsiveness to noxious stimulation were performed at each concentration.
Monitoring of clinical responsiveness to noxious stimuli
Clinical responsiveness was assessed at each concentration by repeated administration of transcutaneous electrical stimuli to the right ulnar nerve at an intensity comparable with surgical stimulation (30 s tetanic stimulation at 80 mA; NS252, Fisher & Paykel Healthcare Ltd., Auckland, New Zealand). 10 Before, during, and after every stimulus, the heart rate was measured continuously, based on a beat-by-beat analysis of the ECG as integrated in the applied clinical monitoring system (Precess 3160, Invivo, Gainesville, FL, USA). Noxious stimulation was not started before the heart rate was stable (variation of less than 2 beats min À1 ) for at least 1 min. The maximum heart rate during the 30 s tetanic stimulation until 30 s after the end of the stimulation was considered the 'poststimulus' heart rate. The blood pressure was determined non-invasively using the same monitoring system once immediately before the noxious stimulation and once immediately after the end of the stimulation. Positive responses of heart rate and blood pressure to the noxious stimulation were defined as increases of more than 
Monitoring of spinal and brain responsiveness to noxious stimuli
Spinal and brain responsiveness to noxious stimulation was assessed by repeated application of transcutaneous electrical stimuli to the sural nerve at the left malleolus. Each stimulus consisted of a train of five rectangular pulses of 1 ms duration delivered at 200 Hz (DS5, DS7; Digitimer Ltd, Welwyn Garden City, UK). In contrast to the monitoring of clinical responsiveness, we used a different stimulation site (sural nerve instead of ulnar nerve) with a different stimulation paradigm (train-of-five stimulation instead of tetanic stimulation) to be able to monitor the spinal responsiveness by quantification of the nociceptive flexion reflex simultaneously to the monitoring of brain responsiveness by quantification of somatosensory evoked potentials and blood-oxygen-level dependent (BOLD)-fMRI activations. Individual stimulus intensities were determined before starting the main experimental procedure: 'innocuous' stimulation intensities were defined as stimuli that were perceived but rated as innocuous (0.5e3 mA), and 'moderate noxious' stimulation intensities were defined as stimuli that were rated as painful but could be endured over multiple repetitions (4e25 mA). To test responses to stimuli that mimic clinical conditions during surgery, 'intense noxious' stimuli at intensities comparable with surgical stimulation were predetermined (50e100 mA).
Nociceptive flexion reflex acquisition and processing
To monitor spinal neuronal responses to the applied stimuli, we recorded clinically invisible nociceptive flexion reflex responses through surface electromyograms of the left biceps femoris muscle (BrainAmp MR; Brain Products GmbH, Gilching, Germany) and quantified the R3-component of the reflex as a nociception-specific measure. Data were acquired at 5000 Hz to remove the fMRI gradient artefact by subtracting of a sliding average of recordings without stimuli. Further analysis was performed after down-sampling to 250 Hz and bandpass filtering between 0.2 and 48 Hz (Fig. S3C) . To quantify the reflex responses, the area under the curve (AUC) of the rectified EMG in the time window 90e150 ms after the stimulus was calculated for each stimulus and baseline-adjusted by subtracting of the AUC of the baseline in the time window 70e10 ms before the stimulus. 11, 12 Population averages were calculated from individual means for the innocuous stimuli, the moderate noxious stimuli and the intense noxious stimuli at each anaesthetic concentration.
EEG acquisition and processing
To ascertain that the pharmacologically induced changes in the fMRI are a result of neuronal effects and not a result of changes in the neurovascular coupling, we simultaneously recorded the somatosensory evoked potentials in the EEG of the primary somatosensory cortex as a direct measure of neuronal activity. 13 The somatosensory evoked potentials elicited by the stimuli to the sural nerve were quantified through 32 channel surface EEGs (BrainAmp MR, Brain Products GmbH). Scalp electrodes were placed according to the international 10e20 system. Data were acquired at 5000 Hz to remove the fMRI gradient artefact by subtracting of a sliding average of recordings without stimuli. Further analysis was performed after down-sampling to 250 Hz and band-pass filtering between 0.1 and 48 Hz. As the closest recording point to the representation of the foot in the somatosensory cortex, the signal of the Cz electrode was re-referenced to the average of all other electrodes (Fig. S3B) . To quantify the somatosensory evoked potentials at Cz, the AUC of the rectified EEG in the time window from 0 to 400 ms after the stimulus was calculated for each stimulus and baseline-adjusted by subtracting of the mean signal of the baseline in the time window from 100 to 0 ms before the stimulus. 14e16 Population averages were calculated from individual means for the innocuous stimuli, the moderate noxious stimuli and the intense noxious stimuli at each anaesthetic concentration. All data processing and analyses of the somatosensory evoked potentials were performed using SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK) and Matlab R2016a (The MathWorks, Natick, MA, USA).
MRI data acquisition and processing
For the monitoring of brain neuronal responses to the applied stimuli we acquired fMRI data using a 1.5 T Siemens Avanto Scanner (Siemens Healthcare GmbH, Erlangen, Germany). Functional MRI data were acquired using an echo-planar imaging sequence (EPI, TR¼3.01 s, TE¼50 ms, 64Â64 matrix, 3Â3Â3 mm voxels, 35 slices). All data processing and analyses of fMRI data were performed using SPM12 and Matlab R2016a.
To investigate the activation of brain areas after noxious stimulation during anaesthesia, fMRI scans were acquired at each remifentanil concentration while the participants received six blocks of innocuous, six blocks of moderate noxious and six blocks of intense noxious stimuli in randomised order. Each block had a length of 30.1 s (10ÂTR) and contained three stimuli of the same intensity at interstimulus intervals of 6.02 s (2ÂTR), starting with the first stimulus directly at the beginning of the block (Fig. 1) , for a total of 18 innocuous stimuli, 18 moderate noxious, and 18 intense noxious stimuli, administered to each subject at each concentration of remifentanil. Outlier images were identified by calculating the Mahalanobis distance of the matrix of imagewise mean and standard deviation (concatenated) Â time, and images with significant c 2 values (P<0.05, Bonferronicorrected) were considered outliers. 17 For each outlier image, a dummy regressor was included into the models. All acquired images were realigned and unwarped, slice time corrected, normalised to MNI space, smoothed (full width at half maximum¼8 mm), and detrended. 18 Standard general linear models were calculated for each participant, containing one regressor for each stimulation intensity convolved with the canonical haemodynamic response function implemented in SPM12, delayed by 6.02 s to account for the delay observed during general anaesthesia (see supplementary appendix for details). To account for data noise, we included the six realignment parameters from the realign preprocessing step, the first three principal components of the signal within the cerebrospinal fluid using a subject-specific mask from segmentation and outlier dummy regressors if applicable. General linear model estimation was performed using robust weighted least squares to compensate for artefacts in the fMRI time series. 19 To generate a mask of brain areas that were activated by intense noxious vs innocuous stimuli during anaesthesia, a population level random-effects model was calculated and the intense noxious stimuli were contrasted against the innocuous stimuli. Clusters of significant activity (uncorrected voxel threshold P<0.001, family-wise error corrected cluster threshold P<0.05) were then extracted (Fig. 3B , Table S1 ) and combined to yield a mask of all brain areas activated during general anaesthesia. We refer to these combined areas as the 'nociception matrix', analogous to the term 'pain matrix' for those brain areas activated by noxious stimulation in conscious subjects. 20 The mean activation across all concentrations was used as brain areas might be dynamically recruited during different levels of general anaesthesia. 21, 22 To quantify the signal change within the 'nociception matrix', the cluster-wise mean BOLD-fMRI regression coefficient was first normalised to its absolute maximum value for each cluster and each subject separately. The signals from all clusters were then averaged to yield the individual participants' nociception matrix signals, which were then averaged across the participant sample.
To determine those brain areas in which the activation after intense noxious stimulation vs innocuous stimulation was significantly dependent on the remifentanil concentration, we first generated subject-specific maps contrasting activations after intense noxious stimuli against activations after innocuous stimuli during each level of anaesthesia. These contrasts were then used in a random-effects analysis, and a descending parametric contrast was used to compare maps of the four states of anaesthesia during which remifentanil was additionally administered (i.e. excluding the propofol mono-anaesthesia state).
To evaluate the functional connectivity between the brain areas of the nociception matrix across remifentanil concentrations, the BOLD-fMRI time series within these were denoised using the first principal component of the time series within the subject-specific CSF and white matter mask, the six realignment parameters from the realignment pre-processing step, outlier dummy regressors and the stimulation time points convolved with SPM12's canonical haemodynamic response function (delay¼6.02 s, see supplementary appendix for details). Different from the outlier regressors in the taskfMRI analysis, outlier volumes were here defined as volumes with a framewise displacement of >0.5 mm or a DVARS (whole-brain root mean square of differentiated time series) deviating >2 standard deviations from the mean, as functional connectivity is very sensitive to movement-related artefacts. 23 The subjects had a mean (SD) fraction of outlier images of 3.1% (1.2%), 3.9% (1.3%), 3.6% (1.5%), and 3.5% (1.1%) at remifentanil concentrations of 1, 2, 4, and 8 ng ml À1 , respectively. The time series were band-pass filtered between 0.008 and 0.09 Hz and linearly detrended. The denoised time series within each cluster was then correlated with those of all other clusters of the nociception matrix to yield functional connectivity scores.
To evaluate how the functional connectivity depended on the concentration, we generated an ascending parametric contrast across all concentrations with remifentanil infusion, excluding the propofol mono-anaesthesia state. All functional connectivity processing was performed using the CONN functional connectivity toolbox 17f. 24 
Fig 1.
Experimental sequence. Illustration of the experimental sequence in the unconscious subjects during steady propofol sedation. At each effect-site concentration level of remifentanil (top row), 6 blocks of innocuous (green), 6 blocks of moderate noxious (yellow), and 6 blocks of intense noxious (red) stimuli were applied in randomised order (middle row). Within each stimulation block, the electrical stimulation was administered three times at an inter-stimulus interval of 6 s with the first stimulus directly at the beginning of the block (bottom row).
Statistical analysis
For each measure of spinal or brain activation (nociceptive flexion reflex, somatosensory evoked potentials, fMRI of the nociception matrix) we calculated a 3Â5 (stimulus intensities Â remifentanil concentrations) repeated measures analysis of variances (RM-ANOVA) using Dunnett's post hoc tests to analyse whether the responses to the noxious stimuli differed from those of the innocuous control stimuli.
Results
The 10 volunteers included in this study (five female and five male) had a median age of 24 (19e28) Measures of spinal or brain activation are able to differentiate between intense noxious stimuli and innocuous stimuli during general anaesthesia
All three measures of spinal or brain activationdthe nociceptive flexion reflex, the fMRI of the nociception matrix, and the somatosensory evoked potentials of the somatosensory cortexdconsistently showed significant differences between the intense noxious stimuli and the innocuous control stimuli at all concentrations of remifentanil (P<0.05 for each, Dunnett's post hoc tests to the RM-ANOVA; see supplementary appendix for P values). During moderate noxious stimulation, the nociceptive flexion reflex as a nociception-specific measure of spinal nociception did not show any significant differences in comparison with the innocuous control (P>0.05, Dunnett's post hoc test to the RM-ANOVA; Fig. 2B ), whereas the unspecific measure of neuronal activation, the somatosensory evoked potentials, showed a significant difference for most concentrations (P<0.05, Dunnett's post hoc test to the RM-ANOVA; Fig. 2C ). The fMRI of the nociception matrix showed a significant difference between moderate and innocuous stimuli at the propofol mono-anaesthesia level and at a remifentanil effect-site concentration of 4 ng ml À1 (P<0.05, Dunnett's post hoc test to the RM-ANOVA; see supplementary appendix for exact P values; Fig. 2D ).
BOLD-fMRI activations after intense noxious stimuli persist during deep general anaesthesia in multiple brain regions
When contrasting the BOLD-fMRI signal responses evoked by the intense noxious stimuli against the signal responses to the innocuous stimuli separately for each remifentanil concentration, we observed persistent significant signal responses in multiple brain regions, especially in the frontal brain (Fig. 3) . The extent of the activations was dependent on the remifentanil concentration, with an increase under low remifentanil effect-site concentrations in comparison with measurements without remifentanil, followed by a dosedependent reduction of activation under higher remifentanil effect-site concentrations. Other than the intense noxious stimuli, the moderate noxious stimuli did not cause any activations that significantly differed from those evoked by the innocuous stimuli (uncorrected voxel threshold P<0.001, family-wise error corrected cluster threshold P>0.05). The observed decrease of activation at higher remifentanil concentrations was accompanied by a decreased functional connectivity between the clusters of the nociception matrix ( Fig. 4 ; false discovery rate seed-level corrected P<0.05, two sided).
Discussion
We were able to demonstrate that noxious stimuli at intensities comparable with surgical stimulation provoke activation in the spinal cord and the brain (i.e. nociception) during deep general anaesthesia that is currently considered clinically sufficient. Even considerably higher doses of the analgesic than are usually applied in current clinical practice only reduced spinal and brain activation to 41% of the maximal response. Clinical responses, such as movement, heart rate, and blood pressure elevations, were absent at far lower doses and were therefore not indicative of spinal and brain activation.
To quantify spinal and brain activation under general anaesthesia, we applied a novel comprehensive approach, combining three neurophysiological measures in one setup. The first component, the nociceptive flexion reflex, allows a highly specific and sensitive assessment of spinal nociception in awake subjects 11 and in subjects under general anaesthesia. 25, 26 It constitutes an experimental means of standardising the paradigm of 'movement responses evoked by noxious stimulation', which is the current gold standard for the measurement of acute pain in animals, 27, 28 and in unconscious or anaesthetised humans. 29 Applicability of the nociceptive flexion reflex has been demonstrated for a wide range of different anaesthetic regimes. 25,26,30e32 As the nociceptive flexion reflex only reflects the spinal level of nociception, we combined it with BOLD-fMRI and EEG to assess nociception in the brain. BOLD-fMRI allows a spatial discrimination of brain activation and therefore allows us to quantify activations located in those areas of the brain that are activated after noxious stimulation. Weighted averaging of the BOLD-fMRI signal from the brain regions activated by noxious stimuli in conscious subjectsdthe so-called 'pain matrix'dhas been previously validated as a highly specific measure of physical pain. 17 However, the pain matrix of conscious subjects might not contain all the brain regions relevant for the processing of nociception during general anaesthesia, as the noxious stimuli applied during general anaesthesia by far exceed the intensity of stimuli that can be endured by conscious subjects. Moreover, different brain areas might be dynamically recruited for the processing of noxious stimulation depending on the level of general anaesthesia.
21,22
Therefore, we performed our analyses based on a matrix that includes all brain areas that were activated by intense noxious vs innocuous stimuli in subjects during general anaesthesia, which we termed 'nociception matrix'. The nociception matrix includes several brain regions that have been commonly observed in pain-related studies to be activated by noxious stimuli in awake subjects: the anterior cingulate cortex, the right insula, the cerebellum, the bilateral secondary somatosensory cortices, and the right putamen.
9,22,33e35 Interestingly, two components that we identified in the nociception matrix, namely clusters in the orbitofrontal cortex and in the right angular gyrus, are part of the 'default mode network', a resting state network that is active during task-free rest. 36 It has been suggested that the anticipation of painful stimuli reduces the activity in the default mode network, 37, 38 while the actual perception of painful stimuli increases the activity, 39 even surpassing resting conditions in some areas such as the right (but not left) angular gyrus. 37 Thus, the activation of components of the default mode network after noxious stimuli in unconscious subjects in our study might be even increased because pain anticipation is not possible in unconscious subjects. The middle and inferior temporal gyri, in which we identified activations that contribute to the nociception matrix, are less well characterised brain regions in pain-related studies; however, have previously been implicated in pain processing.
38,40 However, activations in the BOLD-fMRI are not necessarily specific for neuronal activation, especially under pharmacological influences that might affect the neurovascular coupling and thus the BOLD-effect. Apart from direct pharmacological effects on neurovascular coupling, indirect effects such as pharmacologically induced respiratory changes leading to changes in end-tidal CO 2 partial pressure might also influence the dynamics of the BOLD-effect. 41 Therefore, to prevent such confounding influences, we took special care to keep all subjects at a stable cardiorespiratory level throughout the course of the study, in particular with regard to end-tidal CO 2 . To verify that our measures to prevent confounders influencing BOLD-fMRI activation maps contrasting intense noxious stimuli against innocuous stimuli during general anaesthesia. Shown are the statistical parametric maps (random-effects analysis, n¼10) of the intense noxious stimuli at intensities comparable with surgical stimulation vs the innocuous stimuli (uncorrected voxel threshold P<0.001, family-wise error corrected cluster threshold P<0.05) at every remifentanil concentration levels after the loss of consciousness (A) and the mean activation across all levels after loss of consciousness (B; 'nociception matrix'). C Illustration of the parametric effect of remifentanil concentration, generated by first contrasting activations following intense noxious stimuli against activations following innocuous stimuli within every concentration level of remifentanil, and then using a descending parametric contrast across all remifentanil concentration levels, excluding the propofol mono-anaesthesia state (uncorrected voxel threshold P<0.001, family-wise error corrected cluster threshold P<0.05). Numbers mark coordinates of z-axis in MNI space. Ce, effect-site concentration.
BOLD-fMRI neurovascular coupling were successful, we combined BOLD-fMRI with simultaneous EEG as a direct measure of neuronal activity. 13 Although somatosensory potentials recorded in the EEG cannot be considered nociception-specific, they ensure that the signal changes in the BOLD-fMRI derive from changes in neuronal activity and not from changes in the neurovascular coupling. 42 Given the strong concordance between the measures, it is unlikely that the BOLD-fMRI remifentanil doseeresponse curve is the result of changes in neurovascular coupling or other influences that specifically alter the BOLD-effect. Our results demonstrate that activations in the nociception matrix after intense noxious stimulation persist during all investigated levels of anaesthesia. Furthermore, we demonstrate that the effect size of the activation in the nociception matrix is in concordance with the effect size of nociceptionspecific activation at the spinal level as measured by the nociceptive flexion reflex, and with the effect size of brain neuronal activation as measured by the somatosensory evoked potentials. As the setup used in this study measures both the spinal and brain levels of nociception (content validity) and our effect sizes demonstrate that all three measures are in close concordance for the intense noxious stimuli (criterion validity), we argue that this combined setup is a valid measure of spinal and brain nociception under general anaesthesia. However, we did not measure other components of nociception in our setup, such as brainstem and autonomic responses to noxious stimuli, and these components might show different responsiveness during general anaesthesia than those investigated here.
Regarding each of the measures separately, we observed that the somatosensory evoked potentials, as a signature of unspecific neuronal activation, showed significant responses to each stimulus intensity, even to the innocuous and moderate noxious stimuli, thus supporting the notion that the activations in the somatosensory potentials are not entirely of a nociceptive nature. In contrast, the BOLD-fMRI of the nociception matrix and the nociceptive flexion reflex showed statistically significant responses almost only to the intense noxious stimuli, showing concordance between the nociception-specific nociceptive flexion reflex and the possibly nociception-specific BOLD-fMRI of the nociception matrix. However, our limited sample size means that the negative results, such as the absence of significant activations after moderate noxious stimulation in the BOLD-fMRI, must be regarded with caution.
To further study the brain areas involved in the processing of noxious stimuli during deep general anaesthesia, we contrasted BOLD-fMRI activations after intense noxious stimuli at intensities comparable with surgical stimulation with activations after innocuous stimuli for each opioid concentration. The decrease of nociceptive activation with increasing concentrations of remifentanil is well matched by a decreasing functional connectivity between most areas of the nociception matrix (Fig. 4) . This result indicates that a reduced functional connectivity between the brain areas of the nociception matrix could be responsible for an attenuated processing of noxious stimuli (e.g. by disrupting information transfer). A parametric contrast across remifentanil concentrations showed significant decreases of activity with increasing remifentanil concentration only in the frontal brain areas, which suggests an unchanged processing of intense noxious stimuli in the other brain areas of the nociception matrix. However, the lack of statistically significant decreasing activity in areas other than the frontal brain might be a result of our limited sample size and should therefore be interpreted with caution.
Furthermore, we observed more wide-spread activations in the prefrontal cortex during the administration of low doses of remifentanil than during propofol mono-anaesthesia, which is surprising as remifentanil is expected to have an antinociceptive effect even at low doses. 9 However, as all three measures of nociceptive activation showed an increased effect size during low doses of remifentanil, we attribute this finding to an actual increase in nociceptive processing rather than to a excluding the propofol mono-anaesthesia state (Ce remifentanil 0 ng ml À1 ). Lines indicate significant changes of functional connectivity during increasing remifentanil concentration (false discovery rate seed-level corrected P<0.05, two sided); color indicates the t-value of the connectivity (see Table S7 for P values). OFC/ACC, orbitofrontal cortex/anterior cingulate cortex; MTG, middle temporal gyrus; SII, secondary somatosensory cortex; PostCG, postcentral gyrus; ITG, inferior temporal gyrus; Cb, cerebellum; L, left; R, right; ant, anterior; post, posterior.
potential confounding effect. Therefore, the most likely explanation for less pronounced BOLD-fMRI activations during propofol mono-anaesthesia might be a higher propofol effect-site concentration during these measurements in comparison with the measurements with additional administration of remifentanil, as propofol influences nociceptive processing in a dose-dependent manner. 43, 44 Higher propofol effect-site concentrations during the propofol monoanaesthesia measurements might have been caused by the requirement of most participants for intermittently higher effect-site concentrations of propofol for the insertion of the laryngeal mask. Therefore, the effect-site concentration of propofol might have still been elevated in some participants during the propofol mono-anaesthesia measurements, as these were performed before the measurements with additional administration of remifentanil. To ensure steady effectsite concentrations of propofol, we utilised target-controlled infusion pumps, programmed with the PK/PD model of Schnider. 7 However, we did not verify the stability of concentrations by analysing blood samples or monitoring of EEG indices. In conclusion, the results during propofol monoanaesthesia might not be robust and should be interpreted with caution, as variations of propofol concentration at these levels might have an effect on the brain's ability to process nociceptive input. 44 Nonetheless, our main aim of investigating nociceptive processing during clinically relevant deep anaesthesia with propofol and remifentanil should not have been affected in a relevant way by slight changes of propofol concentrations, as the relative effect of the applied doses of remifentanil on nociceptive processing is far stronger. 45 A similar confounding influence of a delayed onset of remifentanil-induced effects is, however, unlikely, as apart from allowing remifentanil effect-site concentration to equilibrate according to the PK/PD model, we waited additional multiple equilibration half-life periods before commencing the measurements. In summary, our combined findings from BOLD-fMRI, somatosensory evoked potentials, and nociceptive flexion reflex analyses suggest that patients during deep general anaesthesia might respond to noxious stimulation from surgical procedures at the spinal cord and the brain, even when the levels of anaesthesia and antinociception are considered sufficient, based on the absence of clinical responses. Therefore, the important question is whether ongoing nociception during general anaesthesia has clinically relevant adverse effects on patient outcomes. To date, no studies have addressed this problem, which is probably a result of the unavailability of valid nociception measures during general anaesthesia in clinical practice. This poses a typical chicken-or-egg dilemma: the outcome relevance of ongoing nociception during general anaesthesia cannot be determined without validated measures, but conversely, there is little motivation to develop such measures without studies that show outcome relevance. However, the fact that there is still no evidence for adverse effects from ongoing nociception should not be interpreted as proof of their non-existence, as their existence remains largely uninvestigated. In fact, a plausible scientific basis arguing in favour of clinical relevance of ongoing nociception during general anaesthesia does exist. Dosing of analgesics based on clinical responses such as body movements or increases in heart rate or blood pressure prevents the well-established adverse effects of these responses, as movement might interfere with controlled ventilation and haemodynamic responses might cause cardiac stress. 3, 4 However, the 'clinically invisible' neuroendocrine and metabolic stress responses to nociception and the direct neuronal effects of nociception might indeed cause relevant outcome effects, which cannot be prevented by a dosing of analgesics according to clinical responses. For instance, neuroendocrine and metabolic stress responses to noxious stimuli have been shown to exhibit a variety of effects on a number of organs. Specifically, stress responses after noxious stimuli have been found to impair immune function 46 and wound healing, 47 to cause cardiac ischaemia, 48e52 to alter coagulation, 53 to inhibit intestinal motility, 54 and to adversely modify autoregulation of most visceral organs. 55 Furthermore, apart from stress responses, direct neuronal effects of nociception might induce chronic postoperative pain via central sensitisation 56, 57 and contribute to the development of postoperative delirium. 58, 59 In conclusion, there is a variety of mechanisms by which nociception could influence patient outcomes, and not all of these mechanisms can be effectively prevented by dosing of antinociceptive drugs according to clinical responses. However, even though our study shows that nociceptive stimuli are still being processed in the spinal cord and the brain during deep general anaesthesia, it remains unclear whether this processing causes clinically relevant effects. Nociceptive spinal and brain activation during anaesthesia neither means pain perception, as pain is by definition a conscious experience, 60 nor does it necessarily reflect autonomous or humoral stress responses. Activation of brain areas is not even a sure sign of advanced processing and integration of information, especially as general anaesthesia is commonly thought to be caused by a transient breakdown of information integration. 61e63 Low levels of nociception might provoke nociceptive spinal and brain activations as observed in our study, but not cause clinically relevant effects at all, while only higher levels of nociception above a certain threshold might cause relevant responses that influence the patient outcomes. Additionally, as GABAergic anaesthetics such as propofol have been shown to suppress long-term potentiation, 64e66 which is assumed to be a synaptic correlate of learning and memory, nociceptive synaptic activations in anaesthetised subjects might not induce the same long-term effects (e.g. pain chronification) as they would in subjects with unimpaired long-term potentiation. Therefore, the clinical relevance of our findings remains unclear and further studies are necessary to determine at which level spinal and brain activations are related with relevant effects on patient outcomes. Such studies should also include other measures of 'clinically invisible' nociception, such as brainstem activation or stress hormone concentrations to provide a comprehensive model of nociception. If, by such studies, a link between persistent nociceptive processing and patient outcome can be established, the next step would be to investigate how this processing might be prevented by multimodal antinociceptive strategies. The most parsimonious antinociceptive strategy that is simply increasing opioid doses to prevent negative effects of persistent nociception might even be counterproductive for the clinical outcome because of dose-dependent deleterious effects such as opioidinduced hyperalgesia. 67 
Limitations
This study was conducted on a rather small sample size of 10 healthy subjects, which might affect the generalisability and reliability of our findings. As an advantage of the small sample size it can be expected that the significant results we found hold a rather large effect sizedas a small sample size requires a large effect size to obtain significant results 68 dand our findings should therefore be reproducible in larger cohorts. However, as we used random-effects analyses, a small sample size such as ours might not produce reliable results in case of one or several subjects being outliers regarding their fixed effect or their within-subject variance. We have therefore estimated the robustness of the random-effects analyses using jack-knife resampling and found that the results of these analyses prove robust within our sample (Fig. S6) . Furthermore, we have performed equivalent fixed-effects analyses, which are included in the supplementary appendix (Fig. S7) , showing no qualitative differences to the random-effects analyses. Thus, our results appear robust across subjects and statistical methods and can be regarded as reliable for the investigated population and populations alike. However, we only studied healthy subjects, and thus further studies in clinically representative samples are required to generalise the results to all patients receiving general anaesthesia.
Another relevant limitation might be that each subject in our study received remifentanil concentrations in an ascending order. Our results could therefore potentially be biased by an order effect as any time-dependent effect could influence the measurements in the same way as dose-dependent effects. In particular, influences that are able to affect all three of our investigated measures of nociception, such as habituation because of repeated stimulation, which is commonly seen for similar noxious stimulation protocols, would be difficult to differentiate from dose-dependent effects in our study design. Therefore, to confirm that no habituation to the noxious stimulation occurred and to control for any other order effects influencing nociceptive processing, we recorded the nociceptive flexion reflex threshold in each subject before, during, and after the infusion of remifentanil and found that the threshold significantly increased at remifentanil effect-site concentrations of 4 and 8 ng ml À1 compared with the pre-remifentanil level (P<0.05 each; Dunn's multiple comparisons test to the Friedman test), but returned to the pre-remifentanil level after discontinuation of the infusion (P>0.99; Dunn's multiple comparisons test to the Friedman test; Fig. S8 ). Regarding our setup, another limitation might be that we used two different stimulation sites for noxious stimulation: to monitor clinical responsiveness we applied noxious stimuli to the ulnar nerve, as tetanic stimulation to this nerve is a validated and reliable experimental pain model mimicking surgical stimuli. 10 To monitor spinal and brain activation we applied noxious and innocuous stimuli to the sural nerve, as this stimulation site allowed us to monitor spinal nociceptive activation through quantification of the nociceptive flexion reflex amplitude. Therefore, our results might be biased as a result of differences in stimulation intensity between the two sites, even though the intensity at both stimulation sites was adjusted to be comparable with the intensity of surgical stimuli, based on the half maximal effective concentrations and minimum alveolar concentration values associated with these stimuli. 30,31,69e71 
